NEW YORK (Diya TV) — Donna Gustafson expected to battle jet lag after a long flight to Australia. Instead, she received news just two days into her trip, doctors told her she had pancreatic cancer. Gustafson, now 72, had noticed her skin turning yellow. She first thought it was dehydration. But doctors quickly confirmed a far more serious diagnosis. Within days, she returned home to Florida for surgery. That moment marked the start of a groundbreaking treatment journey involving a personalized mRNA cancer vaccine.
Doctors diagnosed Gustafson with Stage 2 pancreatic cancer. Surgeons removed the tumor just nine days later. Soon after, her care team introduced her to a clinical trial using personalized mRNA vaccines. At the time, in early 2020, mRNA technology had not yet become widely known. Months later, it would gain global attention during the COVID-19 pandemic. But for Gustafson, it offered a new kind of hope.
She agreed to join the trial without hesitation. Survival rates for pancreatic cancer remain low. Fewer than 13% of patients live beyond five years. Many cases go undetected until the disease reaches an advanced stage. There are no routine screening tests, and treatment options are limited.
Personalized mRNA cancer vaccines are part of a growing field known as cancer immunotherapy. These vaccines train the immune system to recognize and attack cancer cells. Doctors first remove the tumor through surgery. Then scientists analyze the tumor’s genetic material. Using this data, they design a custom vaccine tailored to each patient. The vaccine helps the body identify and destroy leftover cancer cells.
Patients in the trial also received chemotherapy, which remains standard after surgery for pancreatic cancer. Unlike traditional treatments, the vaccine does not directly kill tumors. Instead, it helps prevent cancer from returning by strengthening the immune response.
Gustafson became the first patient in the trial to receive the personalized vaccine. She completed nine doses. Her immune system responded strongly, producing specialized cells known as T cells. These cells target and destroy cancer cells. In the Phase 1 trial, eight out of 16 patients showed a similar immune response. Six years later, most of those patients are still alive. Gustafson’s cancer has not returned.
Researchers say this marks an important step forward. Pancreatic cancer has long resisted immunotherapy. Many experts once believed the immune system could not effectively fight it. However, the study suggests otherwise. Patients who developed a strong immune response lived longer than those who did not.
Scientists are now studying how the vaccines trigger lasting protection. They have identified two key types of T cells involved in the process. “Killer” T cells directly attack cancer cells. “Helper” T cells support and sustain the immune response over time. Together, they may create a more durable defense against cancer recurrence. Researchers believe both types are essential for long-term success. This insight could help improve future cancer vaccines.
While the results are encouraging, experts urge caution. The trial involved a small number of patients. Larger studies are needed to confirm the findings. Some patients naturally survive longer with pancreatic cancer. Researchers must determine whether the vaccine alone drives the improved outcomes. Still, the findings have sparked optimism in the medical community. They suggest that immunotherapy may work better in early-stage cancers than in advanced cases.
Drugmakers have already launched a larger Phase 2 clinical trial to test the vaccine further. Scientists are also exploring other approaches. One promising strategy targets a protein called KRAS. This protein appears in up to 90% of pancreatic cancer cases. Early research shows strong immune responses in many patients. Experts believe multiple treatments will be necessary. Cancer cells often adapt and resist single therapies. A combination of vaccines and other treatments may offer the best results.
For Gustafson, the experimental therapy has made a lasting difference. Six years after treatment, she remains cancer-free. Her case highlights the potential of personalized medicine. While more research is needed, mRNA cancer vaccines could change how doctors treat some of the most aggressive cancers. The early results offer something rare in pancreatic cancer care — renewed hope.
